Comparative Pharmacology
Head-to-head clinical analysis: APRISO versus AZULFIDINE EN TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRISO versus AZULFIDINE EN TABS.
APRISO vs AZULFIDINE EN-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene synthesis, scavenging free radicals, and activating peroxisome proliferator-activated receptor-gamma (PPAR-γ).
Sulfasalazine is a prodrug that is cleaved by colonic bacteria to 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis. It also scavenges reactive oxygen species and inhibits NF-κB activation, leading to anti-inflammatory effects.
1.5 g (3 capsules) orally once daily in the morning. Each capsule contains 0.5 g mesalamine.
500 mg orally twice daily, titrated to 1 g twice daily after 2 weeks for rheumatoid arthritis; 2 g daily in divided doses for ulcerative colitis.
None Documented
None Documented
8.6 ± 4.2 hours for mesalamine; after multiple dosing, effective half-life ~12 hours. Clinical context: allows twice-daily dosing.
Sulfapyridine: 12-15 hours (clinical context: dosing interval typically 6-12 hours due to sulfapyridine accumulation; mesalamine: 0.6-1.5 hours, not clinically relevant)
Renal (primarily as acetylated metabolite, ~80%) and fecal (~20%).
Renal (50% as sulfapyridine metabolites, 33% as acetylsulfapyridine, 15% as sulfapyridine glucuronide, 2% as unchanged sulfapyridine; 15-20% as mesalamine metabolites), biliary/fecal (minimal, primarily mesalamine excreted in feces)
Category C
Category C
Aminosalicylate
Aminosalicylate